Baker Fund Stocks Triple Easy. PCYC They Bought at $19 And Is $90 Now.
June 17, 2013 Baker Bros Advisors LLC PortfolioHALO Halozyme Therapeutics Inc 17 - $6.22 $18,346,000 3,182,251 0.48% 6,471,000 1,412,475 3.071 Biotechnology
The Street Paste info to google to verify
That's why when Celldex' great cancer drug, CDX011, delivered a 32% response rate in Phase II testing versus only a 13% rate for traditional treatments, investors took notice. CDX011 offered patients a 10-monthsurvival rate versus only five months normally. The company has filed for accelerated approval from the Food and Drug Administration. Cramer said the company is likely to get it given this drug's promising start
That's why their all raising targets .